Status: Recruiting
PTX3-targeted Antifungal Prophylaxis
This is a prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation strategies for patients with acute myeloid leukemia who receive induction chemotherapy. Allocation strategy based on an invasive mold infection genetic risk will be double-blinded.
Participants needed: 410
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Bochud Pierre-YvesUpdated: Dec 9, 2025Locations: 9
Eligibility criteria
Signed Informed Consent according to national/local regulations. [+3]
Patients with neutropenia (absolute neutrophils count<500 cells/mm3) upon presen... [+13]